Galectin Therapeutics Inc.
NASDAQ:GALTBiotechnology
+$0.05 today
- Market cap
- $196.25M
- Beta
- 0.49
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.40
Volume 0.23M
Average 0.32M
GALT Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Operating Margin history
Percent of revenue · from the income statement
No Operating Margin data reported for this period type.
Operating Margin vs competitors
How GALT compares with its peers on the latest reported figures
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -5199.8% | -1995.4 pp | — | |
| LTM Mar 2026 | -269216.7% | +221748.3 pp | -359490.4 pp | |
| FY2025 | — | — | — | |
LBRXLB Pharmaceuticals Inc Common Stock | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
ENGNenGene Holdings Inc. | FY2025 | — | — | — |
| Peer median (excluding GALT) | -137208.3% | +109876.5 pp | -359490.4 pp | |
Competitors are the stored peer set for GALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 23.82M | 31.74M | 32.13M | 36.57M | 14.29M |
| Selling, General & Admin | 6.36M | 6.62M | 5.94M | 5.86M | 5.8M |
| Operating Expenses | 30.18M | 38.35M | 38.07M | 42.43M | 20.09M |
| Depreciation & Amortization | 41K | 32K | 33K | 37K | 53K |
| EBITDA | (30M) | (37.71M) | (38.24M) | (41.47M) | (23.45M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (30.18M) | (38.35M) | (38.07M) | (42.43M) | (20.09M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 3K | 52K | 230K | 338K | 126K |
| Interest Expense | 489K | 1.03M | 2.79M | 5.54M | 7.33M |
| Other Income / Expenses | (348K) | (424K) | (2.99M) | (4.61M) | (10.75M) |
| Income Before Tax | (30.53M) | (38.78M) | (41.07M) | (47.05M) | (30.84M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (30.53M) | (38.78M) | (41.07M) | (47.05M) | (30.84M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.52) | (0.65) | (0.74) | (0.76) | (0.48) |
| EPS (Diluted) | (0.52) | (0.65) | (0.74) | (0.76) | (0.48) |
| Weighted Avg Shares | 58.53M | 59.39M | 60.16M | 62.31M | 63.9M |
| Weighted Avg Shares (Diluted) | 58.53M | 59.39M | 60.16M | 62.31M | 63.9M |
Galectin Therapeutics Inc.
NASDAQ:GALT
Intrinsic Alpha fair value
Locked
Current Price
$2.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.